



PATENT
ATTORNEY DOCKET NO.: TNX98-03-01
CUSTOMER NO: 26839



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:)	
Ni, Paul et al.)	
)	Group Art Unit: 1647
Serial No.: To BE Assigned)	
Cont. of 09/303,155)	Examiner: L. Spector
)	
Filed: February 8, 2002)	
)	
For: G-CSF RECEPTOR AGONIST)	
ANTIBODIES AND SCREENING)	
METHODS THEREFOR)	
Assistant Commissioner for Patents	-	
Washington, D.C. 20231		

Dear Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants submit the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing of the first Office Action on the Merits of the above-referenced application. If there are any fees due in order to consider the references, please charge our deposit account 20-0087.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached PTO 1449 form.

This submission does not represent that a search has been made or that no other documents exist which may be material to the examination of this application and does not constitute an admission that any of the listed documents, or any part thereof,

Application No.: Continuation of 09/303,155
Attorney Docket No.: TNX 98-03-01
Customer No.: 26839


are material or constitute prior art under title 35 of the United States code. Applicants reserve the right to present evidence that any of such documents are not prior art.


Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Respectfully Submitted,

Dated: February 8, 2002.

BY:


Cheryl A. Liljestrand
Reg. No. 45,275



Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET OF

Complete if Known

Application Number To Be Assigned

Filing Date February 8, 2002

First Named Inventor Ni et al.

Group Art Unit 1647

Examiner Name Lorraine Spector

Attorney Docket Number TNX98-03-01

10/07/962
10/07/962
02/08/02

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Documents		U.S. Patent Document Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number	Kind Code (if known)			
	5,506,107	B1	Cunnigham et al.	04-09-1996	
	5,665,863	B1	Yeh et al.	09-09-1997	
	5,362,853	B1	Kuga et al.	11-08-1994	
	5,581,476	B1	Osslund	12-03-1996	
	5,981,551	B1	Luengo et al.	11-09-1999	

FOREIGN DOCUMENTS

Examiner Initials	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
	Office	Number	Kind Code (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET OF

Complete if Known

Application Number To Be Assigned

Filing Date February 8, 2002

First Named Inventor Ni et al.

Group Art Unit 1647

Examiner Name Lorraine Spector

Attorney Docket Number TNX98-03-01

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s),	T 2
		LAYTON, J. et al., "Identification of a Functional Domain of Human Granulocyte Colony-Stimulating Factor Using Neutralizing Monoclonal Antibodies," J. Biol. Chem. 266:23815-23821 (1991).	
		Schneider, H. et al., "Homodimerization of Erythropoietin Receptor by a Bivalent Monoclonal Antibody Triggers Cell Proliferation and Differentiation of Erythroid Precursors," Blood 89:473-482 (1997).	
		Syed, R. et al., "Efficiency of Signalling through Cytokine Receptors Depends Critically on Receptor Orientation," Nature 395:511-516 (1998).	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.